Literature DB >> 10050991

Salivary gland carcinomas--prognostic factors.

M H Therkildsen1, M Christensen, L J Andersen, T Schiødt, H S Hansen.   

Abstract

A retrospective study of factors of prognostic significance for clinical course and survival was performed using uni- and multivariate analyses in 251 patients with primary salivary gland carcinoma admitted during the period 1958-1992. Univariate analyses indicated that site of primary tumour, histology, clinical stage, presence of node metastases at primary diagnosis, and status of surgical margins were important prognostic factors for cause-specific survival, locoregional control and distant metastases. Multivariate analyses confirmed that histology was important for both locoregional control and cause-specific survival, whereas primary site was only of importance for locoregional control. Presence of node metastases at diagnosis was more important for locoregional control than clinical stage, whereas clinical stage was the most important factor for cause-specific survival. Status of surgical margins was of major importance for both cause-specific survival and locoregional control. Radiotherapy in addition to surgery improved locoregional control only, whereas survival was not affected.

Entities:  

Mesh:

Year:  1998        PMID: 10050991     DOI: 10.1080/028418698430089

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  15 in total

1.  Tumors of the sublingual gland: a national clinicopathologic study of 29 cases.

Authors:  Simon Andreasen; K Bjørndal; T K Agander; I Wessel; P Homøe
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-03-25       Impact factor: 2.503

2.  Parotid carcinoma: Current diagnostic workup and treatment.

Authors:  Vincent L M Vander Poorten; Francis Marchal; Sandra Nuyts; Paul M J Clement
Journal:  Indian J Surg Oncol       Date:  2010-11-21

3.  Clinicopathologic features as stronger prognostic factors than histology or grade in risk stratification of primary parotid malignancies.

Authors:  Rohan R Walvekar; Pedro A Andrade Filho; Raja R Seethala; William E Gooding; Dwight E Heron; Jonas T Johnson; Robert L Ferris
Journal:  Head Neck       Date:  2011-02       Impact factor: 3.147

4.  [Salivary gland tumors: pathology and prognosis].

Authors:  S Schwarz-Furlan
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

Review 5.  Salivary gland carcinomas.

Authors:  Tobias Ettl; Stephan Schwarz-Furlan; Martin Gosau; Torsten E Reichert
Journal:  Oral Maxillofac Surg       Date:  2012-07-29

6.  Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer.

Authors:  Tobias Ach; Katharina Zeitler; Stephan Schwarz-Furlan; Katharina Baader; Abbas Agaimy; Christian Rohrmeier; Johannes Zenk; Martin Gosau; Torsten E Reichert; Gero Brockhoff; Tobias Ettl
Journal:  Virchows Arch       Date:  2012-12-15       Impact factor: 4.064

7.  Racial and Ethnic Disparities in Salivary Gland Cancer Survival.

Authors:  Joseph L Russell; Nai-Wei Chen; Shani J Ortiz; Travis P Schrank; Yong-Fang Kuo; Vicente A Resto
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-06       Impact factor: 6.223

8.  [Prognostic value of immunohistochemistry in salivary gland cancer].

Authors:  T Ettl; S Schwarz; T Kühnel; P Stockmann; T E Reichert; O Driemel
Journal:  HNO       Date:  2008-02       Impact factor: 1.284

9.  Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer.

Authors:  T Ettl; K Baader; C Stiegler; M Müller; A Agaimy; J Zenk; T Kühnel; M Gosau; K Zeitler; S Schwarz; G Brockhoff
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640

Review 10.  Salivary gland neoplasms.

Authors:  Terry A Day; John Deveikis; M Boyd Gillespie; John K Joe; Besim Ogretmen; J David Osguthorpe; Susan G Reed; Mary S Richardson; Michael Rossi; Ranjiv Saini; Anand K Sharma; Robert K Stuart
Journal:  Curr Treat Options Oncol       Date:  2004-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.